Mirum Pharmaceuticals

biopharmaceutical company

MIRM Nasdaq ISIN US6047491013 SEC CIK 1759425 LEI 254900YZKR40F7F27K81
Follow Mirum Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $185.7M +39.6% vs same quarter last year
Net income −$40.8M −1503.3% vs same quarter last year
EPS, diluted −$0.87 −1840% vs same quarter last year
Operating cash flow −$4.3M −110.9% vs same quarter last year
Revenue by quarter
$99.4M
$111.6M
$127.8M
$133M
$148.9M
$159.9M
$176.2M
$185.7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$200M$0$200M$400M$600MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$521.3M−$23.4M
FY24$336.9M−$87.9M
FY23$186.4M−$163.4M
FY22$77.1M−$135.7M
FY21$19.1M−$84M
FY20$0−$103.3M
FY19-−$52.6M
FY18--
MarginsShare of revenue
  • Operating margin
  • Net margin
−1000%−750%−500%−250%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−4.2%−4.5%
FY24−26%−26.1%
FY23−58.6%−87.7%
FY22−170.3%−176%
FY21−906.1%−438.9%
FY20--
FY19--
FY18--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0$50M$100MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25$54.9M
FY24$9.3M
FY23−$71.1M
FY22−$120.4M
FY21−$132.8M
FY20−$89.3M
FY19−$39.6M
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Mirum Pharmaceuticals
  • Healthcare median
−600%−400%−200%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearMirum PharmaceuticalsHealthcare median
FY25−4.5%−30.6%
FY24−26.1%−47%
FY23−87.7%−58%
FY22−176%−80.4%
FY21−438.9%−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%